期刊文献+

不同龄小鼠成骨细胞OPG和RANKL表达的变化 被引量:4

Different expressing levels of osteoprotegerin and receptor activator of nuclear factor-κB ligand from osteoblasts of young, adult and aged mice
原文传递
导出
摘要 目的观察来源于不同龄小鼠成骨细胞经雌激素作用后,分泌骨保护素(osteoprotegerin,OPG)、核因子资B受体(receptoractivatorofnuclearfactor-κBligand,RANKL)的变化。方法经雌激素作用前后,反转录-聚合酶链反应(RT-PCR)以及酶联免疫吸附试验(ELISA)测定OPG、RANKL表达的变化。结果经雌激素作用后,幼年组和成年组OPG分泌显著增多,而老年组RANKL表达明显下调。结论雌激素可以刺激成骨细胞分泌OPG,减少RANKL表达,很可能是骨质疏松的发生机制之一,是绝经后骨质疏松发生的重要原因。 Objective To investigate different expressing of OPG and RANKL expression from osteoblasts stimulated with estrogen of young, adult and aged mice changing with age. Method We employed RT-PCR and ELISA methods to measure the OPG/RANKL expression from osteoblasts before and after co-cultured with 17β-estradiol. Results OPG expressing from osteoblasts of the yound and adult mice was significantly increased after stimulated with estrogen, however, RANKL expressing wasn′t decreased significantly, compared to from osteoblasts of the aged. There were no significantly difference among osteoblasts co-cultured with methyl-piperidino-pyrazile (MPP). Conclusion Our results suggest that estrogen may exert its anti-resorptive effects on bone, at least in part, by increasing OPG and decreasing RANKL expression in osteoblasts. Decreased OPG and increased RANKL may be one of important reeasons of postmenopausal osteoporosis.
作者 高飞 霍建忠
出处 《中华风湿病学杂志》 CAS CSCD 2005年第4期219-221,共3页 Chinese Journal of Rheumatology
  • 相关文献

参考文献20

  • 1Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 1998, 95: 3597-3602.
  • 2戴生明.破骨细胞的分化与激活及其在关节炎骨质破坏中的作用[J].中华风湿病学杂志,2004,8(5):312-314. 被引量:15
  • 3Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.Cell, 1997, 89: 309-319.
  • 4Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 1999, 140: 4367-4370.
  • 5Shevde NK, Bendixen AC, Dienger KM, et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA, 2000, 97: 7829-7834.
  • 6Ireland DC, Bord S, Beavan SR, et al. Effects of estrogen on collagen synthesis by cultured human osteoblasts depend on the rate of cellular differentiation. J Cell Biochem, 2002, 86:251-257.
  • 7Bord S, Horner A, Beavan S, et al. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab, 2001, 86: 2309-2314.
  • 8Saika M, Inoue D, Kido S, et al. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2,via estrogen receptor-alpha. Endocrinology, 2001, 142: 2205-2212.
  • 9Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes Dev, 1998, 12: 1260-1268.
  • 10Bonnelye E, Aubin JE. Differential expression of estrogen receptor-related receptor alpha and estrogen receptors alpha and beta in osteoblasts in vivo and in vitro. J Bone Miner Res, 2002, 17:1392-1400.

二级参考文献22

  • 1Jones DH,Kong YY,Penninger JM.Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis,2002,61 (Suppl 2):32-39.
  • 2Khosla S.Minireview:the OPG/RANKI/RANK system. Endocrinology,2001,142:5050-5055.
  • 3Kotake S,Udagawa N,Hakoda M,et al. Activated human T cells direclly induce osteoclastogenesis from human monocytes:possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum,2001,44:1003-1012
  • 4Ziolkowska M,Kurowska M,Radzikowska A,et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
  • 5Takayanagi H,Iizuka H,Juji T,et al.Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.Arthritis Rheum,2000,43:259-269.
  • 6Haynes DR,Crotti TN,Loric M,et al.Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford),2001,40:623-630.
  • 7Kong YY,Feige U,Sarosi I,et al.Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature,1999,402:304-309.
  • 8Teitelbaum SL. Bone resorption by osteoclasts. Science,2000,289:1504-1508.
  • 9Armstrong AP,Tometsko ME, Glaccum M,et al.A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function.J Biol Chem,2002,277:44347-44356.
  • 10Mak TW,Yeh WC.Immunology:a block at the toll gate. Nature,2002,418:835-836.

共引文献14

同被引文献64

引证文献4

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部